Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 79
Competitive USA label for OzempicⓇ
Profile
Efficacy
Safety
Convenience
•
•
•
OzempicⓇ approved in the USA
OzempicⓇ is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with
type 2 diabetes
Ozempic® is approved for use in two therapeutic dosages, 0.5 mg and 1 mg
Statistically significant reduction in HbA1c compared with placebo, sitagliptin, exenatide extended-release
and insulin glargine U100
Statistically significant reduction in body weight confirmed in all trials against all comparators
OzempicⓇ demonstrated a safe and well-tolerated profile across the SUSTAIN programme
In SUSTAIN 6, there were 108 MACE events with OzempicⓇ compared to 146 events with placebo,
equivalent to an event rate of 6.6% with OzempicⓇ and 8.9% with placebo
To be launched in the OzempicⓇ Pen, the latest generation of Novo Nordisk prefilled devices
Once-weekly subcutaneous injections
MACE: Major adverse cardiovascular event
changing
diabetes
novo nordiskView entire presentation